Epstein-Barr Virus-Associated Post-transplant Lymphoproliferative Disease.

Area of Science:

• Virology
• Oncology
• Transplantation Medicine

Background:

• Epstein-Barr virus (EBV) is a common virus, typically transmitted via saliva.
• While usually benign, EBV is linked to various cancers, notably post-transplant lymphoproliferative disease (PTLD).
• PTLD incidence is higher when EBV infection occurs shortly after organ transplantation.

Purpose of the Study:

• To review the association between Epstein-Barr virus and post-transplant lymphoproliferative disease.
• To discuss diagnostic methods, including viral DNA measurement.
• To outline current and future therapeutic and preventive strategies for EBV-associated PTLD.

Main Methods:

• Literature review of EBV and PTLD associations.
• Analysis of diagnostic utility of plasma EBV DNA.
• Summary of treatment modalities and preventative measures.

Main Results:

• EBV is implicated in diverse malignancies, including B and T cell lymphomas, and epithelial/mesenchymal tumors.
• Plasma EBV DNA levels can be a valuable diagnostic marker for PTLD.
• Effective treatments include immunosuppression adjustment, antibody therapies, chemotherapy, and adoptive T cell therapy.

Conclusions:

• EBV is a significant factor in PTLD development post-transplantation.
• Early diagnosis via viral DNA detection is crucial.
• A multi-faceted approach involving treatment and prevention, including potential future vaccines, is essential for managing EBV-related PTLD.